The relationship between alterations in plasma metabolites and treatment responses in antipsychotic-naïve female patients with schizophrenia

References

• Abel KM, Drake R, Goldstein JM. 2010. Sex differences in schizophrenia. Int Rev Psychiatry. 22(5):417–428. doi:10.3109/09540261.2010.515205.
   PubMed Web of Science ®Google Scholar
• Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. 2006. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf. 29(7):587–598. doi:10.2165/00002018-200629070-00004.
   PubMed Web of Science ®Google Scholar
• Alavez-Rubio JS, Juarez-Cedillo T. 2019. ACAT1 as a therapeutic target and its genetic relationship with Alzheimer’s disease. Curr Alzheimer Res. 16(8):699–709. doi:10.2174/1567205016666190823125245.
   PubMed Web of Science ®Google Scholar
• Arrúe A, Dávila R, Zumárraga M, Basterreche N, González-Torres MA, Goienetxea B, Zamalloa MI, Anguiano JB, Guimón J. 2010. GABA and homovanillic acid in the plasma of schizophrenic and bipolar I patients. Neurochem Res. 35(2):247–253. doi:10.1007/s11064-009-0048-z.
   PubMed Web of Science ®Google Scholar
• Bowden JA, Shao F, Albert CJ, Lally JW, Brown RJ, Procknow JD, Stephenson AH, Ford DA. 2011. Electrospray ionization tandem mass spectrometry of sodiated adducts of cholesteryl esters. Lipids. 46(12):1169–1179. doi:10.1007/s11745-011-3609-2.
   PubMed Web of Science ®Google Scholar
• Bristow GC, Bostrom JA, Haroutunian V, Sodhi MS. 2015. Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. Schizophr Res. 167(1–3):57–63. doi:10.1016/j.schres.2015.01.025.
   PubMed Web of Science ®Google Scholar
• Bushe C, Holt R. 2004. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl. 47:S67–S71. doi:10.1192/bjp.184.47.s67.
   PubMedGoogle Scholar
• Bushe C, Yeomans D, Floyd T, Smith SM. 2008. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 22(2 Suppl):56–62. doi:10.1177/0269881107088436.
   PubMedGoogle Scholar
• Cao B, Wang D, Brietzke E, McIntyre RS, Pan Z, Cha D, Rosenblat JD, Zuckerman H, Liu Y, Xie Q, et al. 2018. Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. Amino Acids. 50(8):1013–1023. doi:10.1007/s00726-018-2579-6.
   PubMed Web of Science ®Google Scholar
• Ceskova E, Prikryl R, Libiger J, Svancara J, Jarkovsky J. 2015. Gender differences in the treatment of first-episode schizophrenia: results from the European first episode schizophrenia trial. Schizophr Res. 169(1–3):303–307. doi:10.1016/j.schres.2015.10.013.
   PubMed Web of Science ®Google Scholar
• Chiu PW, Lui SSY, Hung KSY, Chan RCK, Chan Q, Sham PC, Cheung EFC, Mak HKF. 2018. In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res. 193:295–303. doi:10.1016/j.schres.2017.07.021.
   PubMed Web of Science ®Google Scholar
• Cholic Acid. 2012. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
   Google Scholar
• Crow TJ, Delisi LE, Lofthouse R, Poulter M, Lehner T, Bass N, Shah T, Walsh C, Boccio-Smith A, Shields G. 1994. An examination of linkage of schizophrenia and schizoaffective disorder to the pseudoautosomal region (Xp22.3). Br J Psychiatry. 164(2):159–164. doi:10.1192/bjp.164.2.159.
   PubMedGoogle Scholar
• Davison J, O'Gorman A, Brennan L, Cotter DR. 2018. A systematic review of metabolite biomarkers of schizophrenia. Schizophr Res. 195:32–50. doi:10.1016/j.schres.2017.09.021.
   PubMed Web of Science ®Google Scholar
• Eranti SV, MacCabe JH, Bundy H, Murray RM. 2013. Gender difference in age at onset of schizophrenia: a meta-analysis. Psychol Med. 43(1):155–167. doi:10.1017/S003329171200089X.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez A, Seeman MV. 2018. Pharmacotherapy for schizophrenia in postmenopausal women. Expert Opin Pharmacother. 19(8):809–821. doi:10.1080/14656566.2018.1465563.
   PubMed Web of Science ®Google Scholar
• Hoftman GD, Volk DW, Bazmi HH, Li S, Sampson AR, Lewis DA. 2015. Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs. developmental disturbance. Schizophr Bull. 41(1):180–191. doi:10.1093/schbul/sbt178.
   PubMed Web of Science ®Google Scholar
• Huang F, Wang T, Lan Y, Yang L, Pan W, Zhu Y, Lv B, Wei Y, Shi H, Wu H, et al. 2015. Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior. Front Behav Neurosci. 9:70. doi:10.3389/fnbeh.2015.00070.
   PubMed Web of Science ®Google Scholar
• Huang YC, Lin PY, Lee Y, Wu CC, Hsu ST, Hung CF, Chen CC, Chong MY, Lin CH, Wang LJ. 2016. β-hydroxybutyrate, pyruvate and metabolic profiles in patients with schizophrenia: a case control study. Psychoneuroendocrinology. 73:1–8. doi:10.1016/j.psyneuen.2016.07.209.
   PubMed Web of Science ®Google Scholar
• Jia W, Wei M, Rajani C, Zheng X. 2021. Targeting the alternative bile acid synthetic pathway for metabolic diseases. Protein Cell. 12(5):411–425. doi:10.1007/s13238-020-00804-9.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261–276. doi:10.1093/schbul/13.2.261.
   PubMed Web of Science ®Google Scholar
• Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, Pantazopoulos H, Berretta S, Heckers S. 2011. Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res. 131(1–3):165–173. doi:10.1016/j.schres.2011.06.007.
   PubMed Web of Science ®Google Scholar
• Koshiyama D, Kirihara K, Tada M, Nagai T, Fujioka M, Ichikawa E, Ohta K, Tani M, Tsuchiya M, Kanehara A, et al. 2018. Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset. Transl Psychiatry. 8(1):211. doi:10.1038/s41398-018-0261-0.
   PubMedGoogle Scholar
• Li R, Ma X, Wang G, Yang J, Wang C. 2016. Why sex differences in schizophrenia? J Translation Neurosci. 1(1):37–42.
   Google Scholar
• Liu ML, Zheng P, Liu Z, Xu Y, Mu J, Guo J, Huang T, Meng HQ, Xie P. 2014. GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells. Mol Biosyst. 10(9):2398–2406. doi:10.1039/c4mb00157e.
   PubMed Web of Science ®Google Scholar
• Liu Y, Song X, Liu X, Pu J, Gui S, Xu S, Tian L, Zhong X, Zhao L, Wang H, et al. 2021. Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: a targeted metabolomics study. Psychiatry Clin Neurosci. 75(4):138–144. doi:10.1111/pcn.13194.
   PubMed Web of Science ®Google Scholar
• Loureiro CM, da Roza DL, Corsi-Zuelli F, Shuhama R, Fachim HA, Simões-Ambrosio LMC, Deminice R, Jordão AA, Menezes PR, Del-Ben CM, et al. 2020. Plasma amino acids profile in first-episode psychosis, unaffected siblings and community-based controls. Sci Rep. 10(1):21423. doi:10.1038/s41598-020-78559-w.
   PubMed Web of Science ®Google Scholar
• Luo J, Yang H, Song BL. 2020. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 21(4):225–245. doi:10.1038/s41580-019-0190-7.
   PubMed Web of Science ®Google Scholar
• McCarthy MM, Auger AP, Perrot-Sinal TS. 2002. Getting excited about GABA and sex differences in the brain. Trends Neurosci. 25(6):307–312. doi:10.1016/s0166-2236(02)02182-3.
   PubMed Web of Science ®Google Scholar
• McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, Dougherty GG, Yao JK, Kaddurah-Daouk R. 2013. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLOS One. 8(7):e68717. doi:10.1371/journal.pone.0068717.
   PubMed Web of Science ®Google Scholar
• Mednova IA, Boiko AS, Kornetova EG, Semke AV, Bokhan NA, Ivanova SA. 2022. Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia. Life (Basel, Switzerland). 12(12):1972. eng. doi:10.3390/life12121972.
   PubMed Web of Science ®Google Scholar
• Mendrek A, Mancini-Marïe A. 2016. Sex/gender differences in the brain and cognition in schizophrenia. Neurosci Biobehav Rev. 67:57–78. doi:10.1016/j.neubiorev.2015.10.013.
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. 2013. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 39(2):295–305. eng. doi:10.1093/schbul/sbs082.
   PubMed Web of Science ®Google Scholar
• Mohammadi A, Rashidi E, Amooeian VG. 2018. Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. Psychiatry Res. 265:25–38. doi:10.1016/j.psychres.2018.04.036.
   PubMed Web of Science ®Google Scholar
• Owen MJ, Sawa A, Mortensen PB. 2016. Schizophrenia. Lancet. 388(10039):86–97. doi:10.1016/S0140-6736(15)01121-6.
   PubMed Web of Science ®Google Scholar
• Petty F, Kramer G, Feldman M. 1987. Is plasma GABA of peripheral origin? Biol Psychiatry. 22(6):725–732. doi:10.1016/0006-3223(87)90204-6.
   PubMed Web of Science ®Google Scholar
• Purves-Tyson TD, Brown AM, Weissleder C, Rothmond DA, Shannon Weickert C. 2021. Reductions in midbrain GABAergic and dopamine neuron markers are linked in schizophrenia. Mol Brain. 14(1):96. doi:10.1186/s13041-021-00805-7.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Zhang L, He S, Wen H, Yu YM, Cao CH, Li HF. 2016. Plasma metabonomics study of first-Episode schizophrenia treated with olanzapine in female patients. Neurosci Lett. 617:270–276. doi:10.1016/j.neulet.2016.02.031.
   PubMed Web of Science ®Google Scholar
• Quattrone D, Di Forti M, Gayer-Anderson C, Ferraro L, Jongsma HE, Tripoli G, La Cascia C, La Barbera D, Tarricone I, Berardi D, et al. 2019. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychol Med. 49(8):1378–1391. doi:10.1017/S0033291718002131.
   PubMed Web of Science ®Google Scholar
• Quinones MP, Kaddurah-Daouk R. 2009. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 35(2):165–176. doi:10.1016/j.nbd.2009.02.019.
   PubMed Web of Science ®Google Scholar
• Ramos-Loyo J, Medina-Hernández V, Estarrón-Espinosa M, Canales-Aguirre A, Gómez-Pinedo U, Cerdán-Sánchez LF. 2013. Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 44:154–161. doi:10.1016/j.pnpbp.2013.02.007.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thakore JH. 2003. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 160(2):284–289. doi:10.1176/appi.ajp.160.2.284.
   PubMed Web of Science ®Google Scholar
• Schwartz CC, VandenBroek JM, Cooper PS. 2004. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 45(9):1594–1607. doi:10.1194/jlr.M300511-JLR200.
   PubMed Web of Science ®Google Scholar
• Sethi S, Brietzke E. 2015. Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders. Int J Neuropsychopharmacol. 19(3):pyv096. doi:10.1093/ijnp/pyv096.
   PubMed Web of Science ®Google Scholar
• Simić K, Todorović N, Trifunović S, Miladinović Z, Gavrilović A, Jovanović S, Avramović N, Gođevac D, Vujisić L, Tešević V, et al. 2022. NMR metabolomics in serum fingerprinting of schizophrenia patients in a Serbian cohort. Metabolites. 12(8):707. doi:10.3390/metabo12080707.
   PubMed Web of Science ®Google Scholar
• Souza AJ, Cortez IL, Silva NR, Pedrazzi JFC, Domingos LB, Braga MS, Santos-Silva T, Del-Bel EA, Resstel LBM, Li G, et al. 2022. Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABA(A) receptors. Behav Brain Res. 428:113832. doi:10.1016/j.bbr.2022.113832.
   PubMed Web of Science ®Google Scholar
• Svensson T, Inoue M, Sawada N, Mimura M, Tsugane S. 2018. High serum total cholesterol is associated with suicide mortality in Japanese women independently of menopause. Acta Psychiatr Scand. 137(1):80–81. doi:10.1111/acps.12841.
   PubMed Web of Science ®Google Scholar
• Tao Y, Zheng F, Cui D, Huang F, Wu X. 2021. A combination of three plasma bile acids as a putative biomarker for schizophrenia. Acta Neuropsychiatr. 33(1):51–54. doi:10.1017/neu.2020.42.
   PubMed Web of Science ®Google Scholar
• Tasic L, Pontes JGM, Carvalho MS, Cruz G, Dal Mas C, Sethi S, Pedrini M, Rizzo LB, Zeni-Graiff M, Asevedo E, et al. 2017. Metabolomics and lipidomics analyses by (1)H nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis. Schizophr Res. 185:182–189. doi:10.1016/j.schres.2016.12.024.
   PubMed Web of Science ®Google Scholar
• Wang T, Li P, Meng X, Zhang J, Liu Q, Jia C, Meng N, Zhu K, Lv D, Sun L, et al. 2022. An integrated pathological research for precise diagnosis of schizophrenia combining LC-MS/(1)H NMR metabolomics and transcriptomics. Clin Chim Acta. 524:84–95. doi:10.1016/j.cca.2021.11.028.
   PubMed Web of Science ®Google Scholar
• Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, et al. 2011. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 10(12):5433–5443. doi:10.1021/pr2006796.
   PubMed Web of Science ®Google Scholar
• Yan L, Zhou J, Wang D, Si D, Liu Y, Zhong L, Yin Y. 2018. Unbiased lipidomic profiling reveals metabolomic changes during the onset and antipsychotics treatment of schizophrenia disease. Metabolomics. 14(6):80. doi:10.1007/s11306-018-1375-3.
   PubMed Web of Science ®Google Scholar
• Yang F, Wang K, Du X, Deng H, Wu HE, Yin G, Ning Y, Huang X, Teixeira AL, de Quevedo J, et al. 2019. Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia. Psychopharmacology. 236(2):753–762. doi:10.1007/s00213-018-5107-1.
   PubMed Web of Science ®Google Scholar
• Zhang R, Zhang T, Ali AM, Al Washih M, Pickard B, Watson DG. 2016. Metabolomic profiling of post-mortem brain reveals changes in amino acid and glucose metabolism in mental illness compared with controls. Comput Struct Biotechnol J. 14:106–116. doi:10.1016/j.csbj.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen DC, Xiu MH, Yang FD, Haile CN, Kosten TA, Kosten TR. 2012. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry. 73(7):1025–1033. doi:10.4088/JCP.11m07422.
   PubMed Web of Science ®Google Scholar